GKOS vs. WST, BAX, PODD, SWAV, TFX, SOLV, GMED, PEN, STVN, and MMSI
Should you be buying Glaukos stock or one of its competitors? The main competitors of Glaukos include West Pharmaceutical Services (WST), Baxter International (BAX), Insulet (PODD), Shockwave Medical (SWAV), Teleflex (TFX), Solventum (SOLV), Globus Medical (GMED), Penumbra (PEN), Stevanato Group (STVN), and Merit Medical Systems (MMSI). These companies are all part of the "surgical & medical instruments" industry.
West Pharmaceutical Services (NYSE:WST) and Glaukos (NYSE:GKOS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership.
Glaukos received 165 more outperform votes than West Pharmaceutical Services when rated by MarketBeat users. Likewise, 64.70% of users gave Glaukos an outperform vote while only 55.74% of users gave West Pharmaceutical Services an outperform vote.
In the previous week, Glaukos had 14 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 20 mentions for Glaukos and 6 mentions for West Pharmaceutical Services. Glaukos' average media sentiment score of 1.69 beat West Pharmaceutical Services' score of 0.80 indicating that West Pharmaceutical Services is being referred to more favorably in the media.
93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 0.5% of West Pharmaceutical Services shares are held by insiders. Comparatively, 6.4% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
West Pharmaceutical Services has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.
West Pharmaceutical Services has a net margin of 19.42% compared to West Pharmaceutical Services' net margin of -43.15%. Glaukos' return on equity of 20.57% beat West Pharmaceutical Services' return on equity.
West Pharmaceutical Services has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.
West Pharmaceutical Services currently has a consensus price target of $435.20, indicating a potential upside of 38.30%. Glaukos has a consensus price target of $112.27, indicating a potential downside of 1.44%. Given Glaukos' higher possible upside, analysts clearly believe West Pharmaceutical Services is more favorable than Glaukos.
Summary
West Pharmaceutical Services and Glaukos tied by winning 9 of the 18 factors compared between the two stocks.
Get Glaukos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GKOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
